West Pharma Announces Fourth-Quarter and Full-Year 2019 Results


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ West Pharma Announces Fourth-Quarter and Full-Year 2019
West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2019 and introduced full-year 2020 financial guidance.

Fourth-Quarter and Full-Year 2019 Summary (comparisons to prior-year period)

Fourth-quarter 2019 net sales of $470.6 million grew 11.4%; organic sales growth was 12.7%; sales from a recent acquisition contributed an additional 30 basis points of growth; currency translation reduced sales by 160 basis points.

Full-year 2019 net sales of $1.840 billion grew 7.1%; organic sales growth was 10.0%; sales from a recent acquisition contributed an additional 10 basis points of growth; currency translation reduced sales by 300 basis points.

Fourth-quarter 2019 reported-diluted EPS of $0.84 increased 22%. Full-year 2019 reported-diluted EPS of $3.21 increased 17%.

Fourth-quarter 2019 adjusted-diluted EPS of $0.82 increased 12%. Full-year 2019 adjusted-diluted EPS of $3.24 increased 15%.

Company is introducing full-year 2020 financial guidance of net sales in a range of $1.95 billion to $1.97 billion and reported-diluted EPS in a range of $3.45 to $3.55.

"Adjusted-diluted EPS" and "organic sales growth" are Non-U.S. GAAP measurements. See discussion under the heading "Non-U.S. GAAP Financial Measures" in this release.

"I am pleased to report strong fourth-quarter 2019 sales and EPS growth, which continues a trend seen throughout the year," said Eric M. Green, President and Chief Executive Officer. "We had double-digit organic sales growth in all three market units of our Proprietary Products segment. High-value products (HVPs) once again fueled sales growth and gross margin expansion, led by Daikyo® and Westar® components."

Mr. Green continued, "We are introducing full-year 2020 financial guidance that is in line with our long-term financial construct of organic sales growth and operating margin expansion. Our end markets are stable and growing, and we are off to a good start to 2020 with a strong book of committed orders for our high value products, such as NovaPure® and Envision® components, as well as Daikyo Crystal Zenith® containers and our portfolio of self-injection delivery platforms. Our teams across the globe have demonstrated their passion for customers throughout 2019, with new product and services offerings, and are poised to deliver another strong year of sales and profit growth for our business in 2020."

Tags : #Westpharma #Q4result #Financialguidancefor2020

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Vahan.ai Advances Multilingual AI Recruitment with NVIDIA NemotronAugust 25, 2026
Beyond Basic Baby Care: Addressing the Monsoon Surge in Infant Skin Concerns with Salve’s Littloo RangeAugust 25, 2026
100+ Bengaluru Clinics Use QR678® as Indian Hair Regeneration Platform Adds New Patent and Expands GloballyAugust 25, 2026
Healthcare Innovation in India: Real Stories That Are Reshaping the Future of MedicineAugust 25, 2026
Generative AI in Indian Hospitals: Where It Is Actually Making a Difference in 2026August 25, 2026
High Uric Acid and Gout: Symptoms, Causes, Diet, Tests, and Treatment ExplainedAugust 24, 2026
Vitamin D Deficiency in India: Symptoms, Causes, Tests, Treatment and PreventionAugust 24, 2026
SRM College of Pharmacy Hosts Two-Day National Pharmaceutical ConferenceAugust 21, 2026
Atomy India Joins Hands with the Paralympic Committee of India as OfficialNutrition and Wellness PartnerAugust 21, 2026
Thumbay International Pathway - MD Program with Installments and a Direct Route to Residency in RomaniaAugust 21, 2026
THIP wins ‘Breakthrough Digital Patient Education Initiative’ award at India Vaccine Leaders Conclave in PuneAugust 21, 2026
Three Watermelons, a Mannequin Head and a PS5: What India Left Behind on Intercity BusesAugust 21, 2026
Evaluating Thyroid Nodules: Fine Needle Aspiration Cytology (FNAC) and Bethesda ClassificationAugust 21, 2026
Clinical Approaches to Acute Kidney Injury (AKI): Biomarkers, Staging, and Renal Replacement TherapyAugust 21, 2026
Diabetes Care in India: Understanding the Crisis, Bridging the Gaps, and Building a Healthier FutureAugust 21, 2026
Diabetes Management: Lifestyle Changes That Make a Real DifferenceAugust 21, 2026
TagMango introduces New AI capabilities for creator businesses at RISE 2026August 20, 2026
AFib: The Irregular Heartbeat We Need to Stop IgnoringAugust 20, 2026
Nanavati Max Launches Dedicated Cancer Helpline to Support Patients and Families In Their Cancer JourneyAugust 20, 2026